| Year |
Citation |
Score |
| 2021 |
Wang L, Xu M, Hu H, Zhang L, Ye F, Jin J, Fang H, Chen J, Chen G, Broussy S, Vidal M, Lv Z, Liu WQ. A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated Anti-Angiogenic and Anti-Tumor Activities. Frontiers in Pharmacology. 12: 734544. PMID 34658874 DOI: 10.3389/fphar.2021.734544 |
0.682 |
|
| 2020 |
Duflocq S, Zhou J, Huguenot F, Vidal M, Liu WQ. One-pot oxime ligation from peptides bearing thiazolidine and aminooxyacetyl groups. Rsc Advances. 10: 17681-17685. PMID 35515616 DOI: 10.1039/d0ra03235b |
0.63 |
|
| 2019 |
Wang L, Coric P, Broussy S, Di Stasi R, Zhou L, D'Andrea LD, Ji L, Vidal M, Bouaziz S, Liu WQ. Structural studies of the binding of an antagonistic cyclic peptide to the VEGFR1 domain 2. European Journal of Medicinal Chemistry. 169: 65-75. PMID 30856407 DOI: 10.1016/j.ejmech.2019.02.069 |
0.686 |
|
| 2018 |
Gomez-Zepeda D, Taghi M, Smirnova M, Sergent P, Liu WQ, Chhuon C, Vidal M, Picard M, Thioulouse E, Broutin I, Guerrera IC, Scherrmann JM, Parmentier Y, Decleves X, Menet MC. LC-MS/MS-based quantification of efflux transporter proteins at the BBB. Journal of Pharmaceutical and Biomedical Analysis. 164: 496-508. PMID 30453156 DOI: 10.1016/J.Jpba.2018.11.013 |
0.677 |
|
| 2017 |
Trapiella-Alfonso L, Broussy S, Liu WQ, Vidal M, Lecarpentier E, Tsatsaris V, Gagey-Eilstein N. Colorimetric immunoassays for the screening and specificity evaluation of molecules disturbing VEGFs/VEGFRs interactions. Analytical Biochemistry. PMID 29284120 DOI: 10.1016/j.ab.2017.12.029 |
0.648 |
|
| 2017 |
Wang L, Coric P, Zhu K, Liu WQ, Vidal M, Bouaziz S, Broussy S. Synthesis and characterization of water-soluble macrocyclic peptides stabilizing protein α-turn. Organic & Biomolecular Chemistry. PMID 29265149 DOI: 10.1039/c7ob02852k |
0.651 |
|
| 2017 |
Wang L, Zhou L, Reille-Seroussi M, Gagey-Eilstein N, Broussy S, Zhang T, Ji L, Vidal M, Liu WQ. Identification of peptidic antagonists of vascular endothelial growth factor receptor-1 by scanning the binding epitopes of its ligands. Journal of Medicinal Chemistry. PMID 28686443 DOI: 10.1021/acs.jmedchem.7b00283 |
0.681 |
|
| 2017 |
Gomez-Zepeda D, Chaves C, Taghi M, Sergent P, Liu WQ, Chhuon C, Vidal M, Picard M, Thioulouse E, Broutin I, Guerrera IC, Scherrmann JM, Parmentier Y, Decleves X, Menet MC. Targeted unlabeled MRM analysis of cell markers for the study of sample heterogeneity in isolated rat brain cortical microvessels. Journal of Neurochemistry. PMID 28581635 DOI: 10.1111/Jnc.14095 |
0.66 |
|
| 2017 |
Bonhoure A, Vallentin A, Martin M, Senff-Ribeiro A, Amson R, Telerman A, Vidal M. Acetylation of translationally controlled tumor protein promotes its degradation through chaperone-mediated autophagy. European Journal of Cell Biology. PMID 28110910 DOI: 10.1016/J.Ejcb.2016.12.002 |
0.309 |
|
| 2016 |
Gaucher JF, Reille-Seroussi M, Gagey-Eilstein N, Broussy S, Coric P, Seijo B, Lascombe MB, Gautier B, Liu WQ, Huguenot F, Inguimbert N, Bouaziz S, Vidal M, Broutin I. Biophysical Studies of the Induced Dimerization of Human VEGF Receptor 1 Binding Domain by Divalent Metals Competing with VEGF-A. Plos One. 11: e0167755. PMID 27942001 DOI: 10.1371/Journal. |
0.323 |
|
| 2016 |
Rizzo-Padoin N, Chaussard M, Vignal N, Kotula E, Tsoupko-Sitnikov V, Vaz S, Hontonnou F, Liu WQ, Poyet JL, Vidal M, Merlet P, Hosten B, Sarda-Mantel L. [(18)F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to (18)F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases. Nuclear Medicine and Biology. 43: 773-780. PMID 27693672 DOI: 10.1016/j.nucmedbio.2016.08.010 |
0.601 |
|
| 2016 |
Bellesoeur A, Noe G, Thomas-Schoemann A, Huillard O, Naji F, Rangarajan S, Puszkiel A, Alexandre J, Goldwasser F, Blanchet B, Vidal M. Abstract 2038: Sunitinib impact on kinome profiles of peripheral blood mononuclear cells from renal cell carcinoma patients: Do molecular effects correlate with clinical data Cancer Research. 76: 2038-2038. DOI: 10.1158/1538-7445.Am2016-2038 |
0.302 |
|
| 2016 |
Rizzo-Padoin N, Chaussard M, Vignal N, Kotula E, Tsoupko-Sitnikov V, Vaz S, Hontonnou F, Liu WQ, Poyet JL, Vidal M, Merlet P, Hosten B, Sarda-Mantel L. [18F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to 18F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases Nuclear Medicine and Biology. 43: 773-780. DOI: 10.1016/j.nucmedbio.2016.08.010 |
0.59 |
|
| 2015 |
Haidar M, Whitworth J, Noé G, Liu WQ, Vidal M, Langsley G. TGF-β2 induces Grb2 to recruit PI3-K to TGF-RII that activates JNK/AP-1-signaling and augments invasiveness of Theileria-transformed macrophages. Scientific Reports. 5: 15688. PMID 26511382 DOI: 10.1038/srep15688 |
0.615 |
|
| 2015 |
Faivre L, Lecouflet L, Liu WQ, Khadher I, Lahaie C, Vidal M, Legouvello S, Beaumont JL, Bierling P, Rouard H, Birebent B. Quality control of extracorporeal photochemotherapy: Proliferation assay using CFSE validated according to ISO 15189:2007 standards. Cytometry. Part B, Clinical Cytometry. 88: 30-9. PMID 25227323 DOI: 10.1002/cyto.b.21188 |
0.609 |
|
| 2015 |
Wang L, Liu WQ, Saraux N, Vidal M, Broussy S. Solid phase synthesis of constrained 13-membered peptide macrocycles employing Fukuyama-Mitsunobu alkylations Tetrahedron Letters. 56: 2456-2459. DOI: 10.1016/j.tetlet.2015.03.091 |
0.63 |
|
| 2014 |
Wang L, Gagey-Eilstein N, Broussy S, Reille-Seroussi M, Huguenot F, Vidal M, Liu WQ. Design and synthesis of C-terminal modified cyclic peptides as VEGFR1 antagonists. Molecules (Basel, Switzerland). 19: 15391-407. PMID 25264829 DOI: 10.3390/molecules191015391 |
0.675 |
|
| 2014 |
Bonache MÁ, Balsera B, López-Méndez B, Millet O, Brancaccio D, Gómez-Monterrey I, Carotenuto A, Pavone LM, Reille-Seroussi M, Gagey-Eilstein N, Vidal M, de la Torre-Martinez R, Fernández-Carvajal A, Ferrer-Montiel A, García-López MT, et al. De novo designed library of linear helical peptides: an exploratory tool in the discovery of protein-protein interaction modulators. Acs Combinatorial Science. 16: 250-8. PMID 24725184 DOI: 10.1021/Co500005X |
0.35 |
|
| 2011 |
Gautier B, Miteva MA, Goncalves V, Huguenot F, Coric P, Bouaziz S, Seijo B, Gaucher JF, Broutin I, Garbay C, Lesnard A, Rault S, Inguimbert N, Villoutreix BO, Vidal M. Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening. Chemistry & Biology. 18: 1631-9. PMID 22195565 DOI: 10.1016/J.Chembiol.2011.10.016 |
0.616 |
|
| 2011 |
Rabinovich GA, Vidal M. Galectins and microenvironmental niches during hematopoiesis. Current Opinion in Hematology. 18: 443-51. PMID 21912250 DOI: 10.1097/Moh.0B013E32834Bab18 |
0.333 |
|
| 2010 |
Labruère R, Gautier B, Testud M, Seguin J, Lenoir C, Desbène-Finck S, Helissey P, Garbay C, Chabot GG, Vidal M, Giorgi-Renault S. Design, synthesis, and biological evaluation of the first podophyllotoxin analogues as potential vascular-disrupting agents. Chemmedchem. 5: 2016-25. PMID 20979080 DOI: 10.1002/Cmdc.201000305 |
0.562 |
|
| 2010 |
Gautier B, Goncalves V, Diana D, Di Stasi R, Teillet F, Lenoir C, Huguenot F, Garbay C, Fattorusso R, D'Andrea LD, Vidal M, Inguimbert N. Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. Journal of Medicinal Chemistry. 53: 4428-40. PMID 20462213 DOI: 10.1021/Jm1002167 |
0.645 |
|
| 2010 |
Courme C, Gresh N, Vidal M, Lenoir C, Garbay C, Florent JC, Bertounesque E. Synthesis of aryl phosphates based on pyrimidine and triazine scaffolds. European Journal of Medicinal Chemistry. 45: 244-55. PMID 19906464 DOI: 10.1016/J.Ejmech.2009.10.003 |
0.596 |
|
| 2010 |
Labruère R, Gautier B, Testud M, Seguin J, Lenoir C, Desbène‐Finck S, Helissey P, Garbay C, Chabot GG, Vidal M, Giorgi‐Renault S. Inside Cover: Design, Synthesis, and Biological Evaluation of the First Podophyllotoxin Analogues as Potential Vascular-Disrupting Agents (ChemMedChem 12/2010) Chemmedchem. 5: 1958-1958. DOI: 10.1002/Cmdc.201090055 |
0.532 |
|
| 2009 |
Goncalves V, Gautier B, Garbay C, Vidal M, Inguimber N. Cyclic peptides as VEGF receptor antagonist. Advances in Experimental Medicine and Biology. 611: 479-80. PMID 19400273 DOI: 10.1007/978-0-387-73657-0_206 |
0.609 |
|
| 2009 |
Goncalves V, Gautier B, Huguenot F, Leproux P, Garbay C, Vidal M, Inguimbert N. Total chemical synthesis of the D2 domain of human VEGF receptor 1. Journal of Peptide Science : An Official Publication of the European Peptide Society. 15: 417-22. PMID 19387974 DOI: 10.1002/Psc.1133 |
0.618 |
|
| 2009 |
Contino-Pépin C, Parat A, Périno S, Lenoir C, Vidal M, Galons H, Karlik S, Pucci B. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Bioorganic & Medicinal Chemistry Letters. 19: 878-81. PMID 19103485 DOI: 10.1016/J.Bmcl.2008.11.118 |
0.3 |
|
| 2009 |
De Gassart A, Trentin B, Martin M, Hocquellet A, Bette-Bobillo P, Mamoun R, Vidal M. Exosomal sorting of the cytoplasmic domain of bovine leukemia virus TM Env protein. Cell Biology International. 33: 36-48. PMID 18992834 DOI: 10.1016/J.Cellbi.2008.10.001 |
0.323 |
|
| 2008 |
Chopard C, Lenoir C, Rizzato S, Vidal M, Arpalahti J, Gabison L, Albinati A, Garbay C, Kozelka J. Synthetic route to dinuclear platinum(II) complexes [{trans-PtCl(NH3)2}2(mu-L)]2+ (L = aliphatic or heterocyclic diamine) as potential antitumor agents, exploiting the mutual activation of hydroxido ligands and ammonium groups. Inorganic Chemistry. 47: 9701-5. PMID 18817377 DOI: 10.1021/Ic801251K |
0.562 |
|
| 2008 |
Pamonsinlapatham P, Gril B, Dufour S, Hadj-Slimane R, Gigoux V, Pethe S, L'hoste S, Camonis J, Garbay C, Raynaud F, Vidal M. Capns1, a new binding partner of RasGAP-SH3 domain in K-Ras(V12) oncogenic cells: modulation of cell survival and migration. Cellular Signalling. 20: 2119-26. PMID 18761085 DOI: 10.1016/J.Cellsig.2008.08.005 |
0.594 |
|
| 2008 |
Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC, Vidal M, Amson R, Telerman A. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice Cell Death and Differentiation. 15: 1723-1733. PMID 18617898 DOI: 10.1038/Cdd.2008.104 |
0.304 |
|
| 2008 |
Ye YB, Lin JY, Chen Q, Liu F, Chen HJ, Li JY, Liu WQ, Garbay C, Vidal M. The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells. Biochemical Pharmacology. 75: 2080-91. PMID 18455151 DOI: 10.1016/j.bcp.2007.12.021 |
0.739 |
|
| 2008 |
Luzy JP, Chen H, Gril B, Liu WQ, Vidal M, Perdereau D, Burnol AF, Garbay C. Development of binding assays for the SH2 domain of Grb7 and Grb2 using fluorescence polarization. Journal of Biomolecular Screening. 13: 112-9. PMID 18216394 DOI: 10.1177/1087057107312124 |
0.747 |
|
| 2008 |
Goncalves V, Gautier B, Garbay C, Vidal M, Inguimbert N. Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors. Journal of Peptide Science : An Official Publication of the European Peptide Society. 14: 767-72. PMID 18044812 DOI: 10.1002/Psc.965 |
0.637 |
|
| 2008 |
Courme C, Gillon S, Gresh N, Vidal M, Garbay C, Florent JC, Bertounesque E. Terminal alkyne-functionalized triazine by Sonogashira coupling: synthesis of a potential cell signalling inhibitor via click chemistry Tetrahedron Letters. 49: 4542-4545. DOI: 10.1016/J.Tetlet.2008.05.050 |
0.579 |
|
| 2007 |
Goncalves V, Gautier B, Coric P, Bouaziz S, Lenoir C, Garbay C, Vidal M, Inguimbert N. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor. Journal of Medicinal Chemistry. 50: 5135-46. PMID 17900101 DOI: 10.1021/Jm0706970 |
0.641 |
|
| 2007 |
Goncalves V, Gautier B, Regazzetti A, Coric P, Bouaziz S, Garbay C, Vidal M, Inguimbert N. On-resin cyclization of peptide ligands of the Vascular Endothelial Growth Factor Receptor 1 by copper(I)-catalyzed 1,3-dipolar azide-alkyne cycloaddition. Bioorganic & Medicinal Chemistry Letters. 17: 5590-4. PMID 17826090 DOI: 10.1016/J.Bmcl.2007.07.087 |
0.609 |
|
| 2007 |
Goncalves V, Gautier B, Garbay C, Vidal M, Inguimbert N. Development of a chemiluminescent screening assay for detection of vascular endothelial growth factor receptor 1 ligands. Analytical Biochemistry. 366: 108-10. PMID 17482136 DOI: 10.1016/J.Ab.2007.03.027 |
0.58 |
|
| 2007 |
Gril B, Vidal M, Assayag F, Poupon MF, Liu WQ, Garbay C. Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel. International Journal of Cancer. 121: 407-15. PMID 17372910 DOI: 10.1002/Ijc.22674 |
0.745 |
|
| 2006 |
Gril B, Liu WQ, Lenoir C, Garbay C, Vidal M. Affinity chromatography for purification of the modular protein growth factor receptor-bound protein 2 and development of a screening test for growth factor receptor-bound protein 2 Src homology 3 domain inhibitor using peroxidase-linked ligand. Analytical Biochemistry. 351: 93-99. PMID 16480678 DOI: 10.1016/J.Ab.2005.12.032 |
0.653 |
|
| 2005 |
Vidal M, Gasse C, Garbay C, Galons H. Recherche de nouveaux agents anti-angiogéniques : analogues structuraux de la thalidomide Annales Pharmaceutiques FrançAises. 63: 85-89. PMID 15803105 DOI: 10.1016/S0003-4509(05)82255-2 |
0.545 |
|
| 2005 |
Vidal M, Liu W, Gril B, Lenoir C, Garbay C. Inhibitors of tyrosine kinase proteins induced Ras signaling pathway as potential anti-tumor agents Comptes Rendus Chimie. 8: 815-821. DOI: 10.1016/J.CRCI.2005.02.014 |
0.728 |
|
| 2004 |
Dvir H, Harel M, Bon S, Liu WQ, Vidal M, Garbay C, Sussman JL, Massoulié J, Silman I. The synaptic acetylcholinesterase tetramer assembles around a polyproline II helix. The Embo Journal. 23: 4394-405. PMID 15526038 DOI: 10.1038/Sj.Emboj.7600425 |
0.729 |
|
| 2004 |
Vidal M, Liu WQ, Gril B, Assayag F, Poupon MF, Garbay C. [Design of new anti-tumor agents interrupting deregulated signaling pathways induced by tyrosine kinase proteins. Inhibition of protein-protein interaction involving Grb2]. Journal De La Societe De Biologie. 198: 133-7. PMID 15368963 |
0.749 |
|
| 2004 |
Vidal M, Liu WQ, Lenoir C, Salzmann J, Gresh N, Garbay C. Design of peptoid analogue dimers and measure of their affinity for Grb2 SH3 domains. Biochemistry. 43: 7336-44. PMID 15182177 DOI: 10.1021/bi030252n |
0.572 |
|
| 2004 |
Géminard C, De Gassart A, Blanc L, Vidal M. Degradation of AP2 during reticulocyte maturation enhances binding of hsc70 and Alix to a common site on TFR for sorting into exosomes. Traffic (Copenhagen, Denmark). 5: 181-93. PMID 15086793 DOI: 10.1111/J.1600-0854.2004.0167.X |
0.403 |
|
| 2004 |
Liu WQ, Vidal M, Olszowy C, Million E, Lenoir C, Dhôtel H, Garbay C. Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs. Journal of Medicinal Chemistry. 47: 1223-33. PMID 14971902 DOI: 10.1021/Jm031005K |
0.755 |
|
| 2004 |
Vidal M, Liu WQ, Gril B, Assayag F, Poupon M, Garbay C. Nouvelle approche thérapeutique du cancer. Interruption des voies de signalisation dérégulées par inhibition des interactions inter-protéiques : exemple de la protéine Grb2 dans la signalisation induite par les protéines à activité tyrosine kinase Biologie Aujourd'Hui. 198: 133-137. DOI: 10.1051/Jbio/2004198020133 |
0.557 |
|
| 2004 |
Gril B, Assayag F, Poupon M, Vidal M, Liu W, Garbay C. 317 SH3-Grb2 inhibitors inactivate HER2 signaling and enhance the anti-tumor effects of Docetaxel European Journal of Cancer Supplements. 2: 96-97. DOI: 10.1016/S1359-6349(04)80325-2 |
0.536 |
|
| 2004 |
Vo-Hoang Y, Gasse C, Vidal M, Garbay C, Galons H. Efficient synthesis of N-benzyl-3-aminopyrrolidine-2,5-dione and N-benzyl-3-aminopyrrolidin-2-one Tetrahedron Letters. 45: 3603-3605. DOI: 10.1016/J.Tetlet.2004.03.052 |
0.538 |
|
| 2002 |
Saci A, Liu WQ, Vidal M, Garbay C, Rendu F, Bachelot-Loza C. Differential effect of the inhibition of Grb2-SH3 interactions in platelet activation induced by thrombin and by Fc receptor engagement. The Biochemical Journal. 363: 717-25. PMID 11964172 DOI: 10.1042/0264-6021:3630717 |
0.74 |
|
| 2002 |
Nioche P, Liu WQ, Broutin I, Charbonnier F, Latreille MT, Vidal M, Roques B, Garbay C, Ducruix A. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor. Journal of Molecular Biology. 315: 1167-77. PMID 11827484 DOI: 10.1006/Jmbi.2001.5299 |
0.775 |
|
| 2001 |
Vidal M, Gigoux V, Garbay C. SH2 and SH3 domains as targets for anti-proliferative agents. Critical Reviews in Oncology Hematology. 40: 175-186. PMID 11682324 DOI: 10.1016/S1040-8428(01)00142-1 |
0.626 |
|
| 2001 |
Géminard C, Nault F, Johnstone RM, Vidal M. Characteristics of the Interaction between Hsc70 and the Transferrin Receptor in Exosomes Released during Reticulocyte Maturation Journal of Biological Chemistry. 276: 9910-9916. PMID 11133993 DOI: 10.1074/Jbc.M009641200 |
0.354 |
|
| 2000 |
Garbay C, Liu W, Vidal M, Roques BP. Inhibitors of RAS signal transduction as antitumor agents Biochemical Pharmacology. 60: 1165-1169. PMID 11007954 DOI: 10.1016/S0006-2952(00)00428-7 |
0.776 |
|
| 2000 |
Liu W, Vidal M, Mathé C, Périgaud C, Garbay C. Inhibition of the ras-dependent mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties. Bioorganic & Medicinal Chemistry Letters. 10: 669-672. PMID 10762050 DOI: 10.1016/S0960-894X(00)00077-9 |
0.742 |
|
| 2000 |
Rieu S, Géminard C, Rabesandratana H, Sainte‐Marie J, Vidal M. Exosomes released during reticulocyte maturation bind to fibronectin via integrin α4β1 Febs Journal. 267: 583-590. PMID 10632729 DOI: 10.1046/J.1432-1327.2000.01036.X |
0.335 |
|
| 2000 |
Nioche P, Liu WQ, Broutin I, Vidal M, Garbay C, Ducruix A. X-ray structures of complexes of SH2-Grb2 domain with high affinity inhibitors Acta Crystallographica Section a Foundations of Crystallography. 56: s97-s97. DOI: 10.1107/S0108767300022650 |
0.528 |
|
| 1999 |
Liu WQ, Vidal M, Gresh N, Roques BP, Garbay C. Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain. Journal of Medicinal Chemistry. 42: 3737-41. PMID 10479306 DOI: 10.1021/Jm9911074 |
0.748 |
|
| 1999 |
Vidal M, Goudreau N, Cornille F, Cussac D, Gincel E, Garbay C. Molecular and cellular analysis of Grb2 SH3 domain mutants: interaction with Sos and dynamin. Journal of Molecular Biology. 290: 717-730. PMID 10395825 DOI: 10.1006/Jmbi.1999.2899 |
0.613 |
|
| 1999 |
Cussac D, Vidal M, Leprince C, Liu W, Cornille F, Tiraboschi G, Roques BP, Garbay C. A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity The Faseb Journal. 13: 31-39. PMID 9872927 DOI: 10.1096/Fasebj.13.1.31 |
0.772 |
|
| 1998 |
Vidal M, Montiel JL, Cussac D, Cornille F, Duchesne M, Parker F, Tocqué B, Roques BP, Garbay C. Differential interactions of the growth factor receptor-bound protein 2 N-SH3 domain with son of sevenless and dynamin. Potential role in the Ras-dependent signaling pathway. The Journal of Biological Chemistry. 273: 5343-8. PMID 9478994 DOI: 10.1074/JBC.273.9.5343 |
0.619 |
|
| 1989 |
Sechoy O, Vidal M, Philippot JR, Bienvenue A. Interactions of human lymphoblasts with targeted vesicles containing Sendai virus envelope proteins. Experimental Cell Research. 185: 122-131. PMID 2553460 DOI: 10.1016/0014-4827(89)90042-6 |
0.303 |
|
| Show low-probability matches. |